# Scala Biodesign

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/scala-biodesign

- Industry: Biotechnology
- Headquarters: Tel Aviv, Israel
- Website: www.scala-bio.com
- Total disclosed funding: $22M
- Latest round: Series A (Mar 29, 2026)
- Investors on record: 7

## About

Based in Israel, Scala Biodesign Ltd. operates as a biotech company that provides protein engineering solutions for the biotechnology and chemical industries.Based in Tel Aviv, Israel, and founded in 2022, Scala Biodesign Ltd. operates as a biotechnology company that develops proteins for pharmaceutical applications. The company was founded by its CEO, Ravit Netzer, and CTO, Adi Goldenzweig and Sarel Fleishman. In March 2026, Scala Biodesign Ltd. raised ILS 15 million in grant funding from Israel Innovation Authority.
Scala Biodesign offers a biotech-based computational platform that uses artificial intelligence (AI) to design proteins for use in medicine, food technology, and industrial applications. The platform’s proteins can be used to create vaccines and enzymes for various therapeutic and industrial manufacturing applications. The firm offers various biological data analyses and one-shot computational solutions.

## Funding rounds

- Series A, Mar 29, 2026, $16M — IT-Farm Corporation, TLV Partners, Grove, Israel Innovation Authority, Deep Insight, Bullet Ventures
- Seed, Sep 11, 2023, $5.5M — Intel Capital, TLV Partners

## Investors

- Intel Capital (https://capitalatlas.ai/funds/intel-capital) — Seed
- TLV Partners (https://capitalatlas.ai/funds/tlv-partners) — Seed, Series A
- IT-Farm Corporation (https://capitalatlas.ai/funds/it-farm-corporation) — Series A
- Grove (https://capitalatlas.ai/funds/grove) — Series A
- Israel Innovation Authority — Series A
- Deep Insight (https://capitalatlas.ai/funds/deep-insight) — Series A
- Bullet Ventures (https://capitalatlas.ai/funds/bullet-ventures) — Series A